Proton pump inhibitors (PPIs) are commonly used in the treatment of acid-related diseases and widely used because of their high security and less adverse reactions. Due to the effectiveness and safety of PPIs, they are increasingly applied in clinical applications with prescriptions growing in recent years. But the potential adverse reactions caused by long-term application of PPIs have attracted many attentions with contro-versies. Osteoporosis caused by PPIs is noted mostly according to epidemiological statistical analysis, and the mechanism is not clear until now. However, it is generally believed that long-term use of PPIs may interfere with calcium absorption or disturb bone metabolism, and result in increasing the risk of fracture ultimately. With the deepening of the bone metabolism research, there appeared a variety of targeted drugs for treatment of os-teoporosis. In this paper, we review the advance on statistical analysis of epidemiology, pathological mechanism and therapeutic strategy of osteoporosis induced by proton pump inhibitors.%质子泵抑制剂(proton pump inhibitors,PPIs)是一类治疗酸相关疾病的常用药物,由于其安全性高、副作用小而广泛应用.近年来,随着使用PPIs的人逐年增加,长期使用PPIs产生的副作用也随之受到关注.质子泵抑制剂的长期使用造成骨质疏松症大多根据流行病学统计分析而佐证,其机制尚不明确.但研究普遍认为,使用PPIs会使钙吸收降低,干扰骨代谢,进而增加骨质疏松风险.随着骨代谢研究的深入,也出现了多种治疗骨质疏松的靶向药物.本文就长期服用质子泵抑制剂引发骨质疏松的流行病学、相关机制以及药源性骨质疏松治疗的研究进展作一综述.
展开▼
